Skip to content

Did a Controversial Naltrexone Implant Contribute to Julián Figueroa's Death?

A family torn apart by grief—and a medical procedure shrouded in controversy. Could better oversight have saved Julián Figueroa's life?

The image shows a graph depicting the number of overdose deaths involving psychostimulants with...
The image shows a graph depicting the number of overdose deaths involving psychostimulants with abuse potential primarily methamphetamine, by opioid involvement, among all ages from 1999 to 2021. The graph is accompanied by text that provides further information about the data.

Did a Controversial Naltrexone Implant Contribute to Julián Figueroa's Death?

The death of Julián Figueroa in 2023 has reignited debates over the safety of naltrexone implants in Mexico. These unregulated devices, marketed for addiction treatment, have faced criticism for weak evidence and serious health risks. Now, a family dispute has brought fresh scrutiny to their use.

In March 2023, Julián Figueroa received a naltrexone implant—a procedure arranged by Marco Chacón, husband of Figueroa's mother, Maribel Guardia. Medical staff advised that Figueroa stay for monitoring, but Chacón took him home shortly after. According to Figueroa's grandmother, Imelda Garza Túñón, neither she nor Figueroa had been informed about the implant beforehand.

After the procedure, Figueroa continued using substances, leading to partial paralysis. This complication later prevented his admission to a rehabilitation programme. Túñón has since stated that she believes the implant contributed to his death two months later. She also insists that proper rehab could have saved his life.

The case highlights broader concerns about naltrexone implants in Mexico. Over the past five years, clinics have promoted them for opioid and alcohol dependence, claiming sustained craving reduction. Yet, Mexico's health regulator, COFEPRIS, warns of insufficient long-term evidence. Risks include infection, implant rejection, and overdose if patients resume substance use after removal. Reports of unlicensed providers causing harm have led to stronger warnings from authorities.

The tragedy has deepened a public feud between Túñón and Guardia. Both sides continue to blame each other for Figueroa's death, while questions remain over the safety and oversight of the treatment he received.

Naltrexone implants remain in a legal grey area in Mexico, operating without formal approval as medical devices. Figueroa's death has drawn attention to their potential dangers, particularly when used without proper oversight. Health officials continue to urge caution, stressing the need for regulated addiction treatments and thorough patient monitoring.

Read also:

Latest